An interventional study of test and Control in Periodontal Diseases, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-07.
Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Periodontal Diseases with a site in Brazil — 5 open to participants now, 7 under way, 1 of them phase 3. Periodontal Diseases · Brazil.
Among the 64 studies in Periodontal Diseases with a site in Brazil, this one is the 55th largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2023, is one of 39 with no phase, and was the 51st registered.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
Browse Periodontal Diseases studies →5 of the 64 studies in Periodontal Diseases with a site in Brazil are open now. Recruiting first, the newest first:
University of Guarulhos · Sites in Brazil
Ages 18+
University of Campinas, Brazil · Sites in Brazil
Ages 18+
Colgate Palmolive · Sites in Brazil
Ages 30–70
University of Guarulhos · Sites in Brazil
Ages 18+ · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 45 across 559 interventional studies indexed under Periodontal Diseases.
Median enrollment 43 across the 56 interventional studies, 64 across the 8 observational. Of the 43 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
Universidade Federal Fluminense is the lead sponsor of 72 studies on the registry; 13 are open to participants now.
Universidade Federal Fluminense has 3 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 64 studies in Periodontal Diseases with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the use of ozone oil as an adjunctive of non-surgical periodontal treatment (NSPT) on diabetics type 2 patients (DM2) compared to control group with chronic periodontal disease.
The principal question is to evaluate if the ozone oil could improve periodontal clinical parameters.
Thirty-two sites of 16 diabetics type 2 patients (DM2) with moderate to advanced periodontal disease containing two sites with periodontal pocket depth (PPD) of > 5 mm were selected.
The treatment was distributed in 2 groups in the split mouth design: Control- scaling and root planing + saline solution (control) and Test - scaling and root planning + ozone oil
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scaling and root planing + saline solution gel (control) will be adminster at probing depth \> 5mm.
Drug: Control
Scaling and root planing + Ozone Oil will be adminster at probing depth \> 5mm.
Drug: test
Ozone oil used as an adjunctive of scaling and root planing and control,
saline solution 0.09% used as an adjunctive as scaling and root planing
Also known as: Placebo Control
Plaque Index
Percentage
Time frame: baseline
Gingival Index
Percentage
Time frame: baseline
Probing Depth
mm
Time frame: baseline
clinical attachment level
mm
Time frame: baseline
Plaque Index
Percentage
Time frame: 3 months
Gingival Index
Percentage
Time frame: 3 months
Probing Depth
mm
Time frame: 3 months
clinical attachment levels
mm
Time frame: 3 months
Plan to share: Undecided
Started Apr 2023 (actual). Primary completion is estimated for Jun 2023, 1 month after the start.
Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 1 month is below that.
Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade Federal Fluminense